{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG+Control&page=2",
    "query": {
      "intervention": "PEG Control",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG+Control&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T03:13:57.291Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01087762",
      "title": "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spondyloarthropathies"
      ],
      "interventions": [
        {
          "name": "CZP 200 mg Q2W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CZP 400 mg Q4W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB BIOSCIENCES GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2010-03",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01087762"
    },
    {
      "nct_id": "NCT00950248",
      "title": "Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Idebenone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 85,
      "start_date": "2009-11-01",
      "completion_date": "2018-08-06",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00950248"
    },
    {
      "nct_id": "NCT01188772",
      "title": "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 147,
      "start_date": "2010-08",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 22,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188772"
    },
    {
      "nct_id": "NCT00857272",
      "title": "F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Colonoscopy"
      ],
      "interventions": [
        {
          "name": "PEG electrolyte lavage solution + bisacodyl - reformulation",
          "type": "DRUG"
        },
        {
          "name": "PEG electrolyte lavage solution + bisacodyl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braintree Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 308,
      "start_date": "2009-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2010-10-05",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Orange, California • San Diego, California + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Smyrna Beach",
          "state": "Florida"
        },
        {
          "city": "Laurel",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00857272"
    },
    {
      "nct_id": "NCT03328507",
      "title": "A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colonoscopy"
      ],
      "interventions": [
        {
          "name": "BLI4900",
          "type": "DRUG"
        },
        {
          "name": "PEG Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braintree Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 121,
      "start_date": "2017-11-09",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Chula Vista, California • San Diego, California + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Ogden",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03328507"
    },
    {
      "nct_id": "NCT03650452",
      "title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy",
        "Dravet Syndrome",
        "Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 141,
      "start_date": "2018-08-08",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650452"
    },
    {
      "nct_id": "NCT01153919",
      "title": "Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "romiplostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "PEG-interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-06-30",
      "completion_date": "2018-07-14",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153919"
    },
    {
      "nct_id": "NCT03921541",
      "title": "Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arginase I Deficiency",
        "Hyperargininemia"
      ],
      "interventions": [
        {
          "name": "Pegzilarginase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immedica Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2019-05-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 17,
      "location_summary": "Rogers, Arkansas • Orange, California • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921541"
    },
    {
      "nct_id": "NCT00993668",
      "title": "Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Certolizumab pegol",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2009-09",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993668"
    },
    {
      "nct_id": "NCT03119168",
      "title": "Effect of Simethicone on Screening Colonoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adenoma Colon"
      ],
      "interventions": [
        {
          "name": "Simethicone Solution",
          "type": "DRUG"
        },
        {
          "name": "Polyethylenglycol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Texas Tech University Health Sciences Center, El Paso",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 268,
      "start_date": "2017-03-15",
      "completion_date": "2019-04-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-09-29T03:13:57.291Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119168"
    }
  ]
}